Access Biotechnology

Access Biotechnology accounts for 18 tracked companies with verified cap-table data, 18 of which disclose round sizes totalling $4B. The median disclosed raise is $140M, and the largest is ACELYRIN at $758M, ahead of Spyre Therapeutics ($644M) and Hemab ($537M).

The names that recur most often on these co-invested cap tables are Access Biotechnology (18 companies), Atlas Venture (6 companies), OrbiMed (6 companies), RA Capital Management (3 companies), Sanofi Ventures (3 companies), VenBio Partners (2 companies). By latest disclosed round, the market skews Series B (6), Series A (6), Series C (3), Growth (2).

• Companies tracked: 18
• Disclosed funding total: $4B across 18 companies
• Median disclosed raise: $140M
• Largest raise: ACELYRIN — $758M
• Stage mix: Series B 6 · Series A 6 · Series C 3 · Growth 2
• Most recent dated round: 2026-05-01

Best funded Access Biotechnology companies

1. ACELYRIN — $758M (latest: Series C)
2. Spyre Therapeutics — $644M (latest: Growth)
3. Hemab — $537M (latest: IPO)
4. Ventus Therapeutics — $370M (latest: Series C)
5. Escient Pharmaceuticals — $238M (latest: Series C)
6. Halda Therapeutics — $202M (latest: Series B)
7. Upstream Bio — $200M (latest: Series A)
8. Disc Medicine — $153M (latest: Series B)
9. Draig Therapeutics — $140M (latest: Series A)
10. DTx Pharma — $114M (latest: Series B)
11. Matchpoint Therapeutics — $100M (latest: Series A)
12. GRO Biosciences — $91M (latest: Series B)
13. VYNE Therapeutics — $88M (latest: Growth)
14. Eliem Therapeutics — $80M (latest: Series A)
15. Curie Therapeutics — $75M (latest: Series A)

Access Biotechnology — related firms and companies (56)

• ACELYRIN
• Spyre Therapeutics
• Hemab
• Ventus Therapeutics
• Escient Pharmaceuticals
• Halda Therapeutics
• Upstream Bio
• Disc Medicine
• Investors like Plug and Play
• Investors like Western Technology Investment
• Investors like Bessemer Venture Partners
• Investors like Torch Capital
• CuraSen Therapeutics
• DTx Pharma
• Investors like RRE Ventures
• Investors like Bienville Capital
• Investors like Notable Capital
• Investors like Balderton Capital
• Investors like International Finance Corporation
• Investors like Access Biotechnology
• VYNE Therapeutics
• Investors like Floodgate
• Investors like Expansion Venture Capital
• Investors like Atlas Venture
• Investors like Coinbase
• Investors like Venrock
• Investors like Canapi Ventures
• Recludix Pharma
• Draig Therapeutics
• Investors like Salesforce Ventures
• Investors like Uncork Capital
• Investors like Ridge Ventures
• Investors like Headline
• Investors like Ribbit Capital
• Access Biotechnology portfolio companies 2026
• GRO Biosciences
• Investors like Amino Capital
• Investors like Upfront Ventures
• Investors like StepStone Group
• Investors like Matrix
• Investors like Shasta Ventures
• Investors like Initialized Capital
• Curie Therapeutics
• Investors like Script Capital
• Investors like Bain Capital Ventures
• Investors like Primary Venture Partners
• Investors like Slow Ventures
• Investors like Next47
• Investors like Menlo Ventures
• Trefoil Therapeutics
• Matchpoint Therapeutics
• Investors like Mayfield Fund
• Investors like Point72 Ventures
• Investors like Canaan Partners
• Investors like Fika Ventures
• Investors like Alumni Ventures

Access Biotechnology alternatives · All research reports